Real-world Outcomes with Cenobamate (CNB) in a Large Series of Patients with Drug-resistant Epilepsy
Abstract number :
2.387
Submission category :
7. Anti-seizure Medications / 7C. Cohort Studies
Year :
2024
Submission ID :
889
Source :
www.aesnet.org
Presentation date :
12/8/2024 12:00:00 AM
Published date :
Authors :
Presenting Author: Estefanía Conde-Blanco, MD, PhD, MSc – Hospital Clínic de Barcelona
Marta Olivera, MD – Hospital Clínic Barcelona
Fiorella Karina Miraval, MD – Hospital Clinic Barcelona
Isabel Manzanares, NP – Hospital Clínic de Barcelona
Antonio Donaire, PhD – Hospital Clinic Barcelona
María Centeno, MD, PhD – Hospital Clínic de Barcelona
Mar Carreño, MD, PhD – Hospital Clinic Barcelona
Rationale:
Cenobamate (CNB) is a new-generation antiseizure medicine (ASM) that has been shown to be more efficacious in refractory focal epilepsy than previous ASMs. This study provides real-world data on patients with highly resistant epilepsy.
Methods: This was a unicenter, retrospective, observational study. Patients with epilepsy (PWE) ≥18 years, with focal seizures, in clinical practice after commercialization of Cenobamate. Data was obtained from medical records and checked with the patients (by telephone call) if necessary. Primary effectiveness endpoints included reductions (100%, ≥90%, ≥75%, and ≥50%) or worsening in seizure frequency at 3, 6, and 12-month visits. Safety endpoints included rates of adverse events (AEs) and AEs leading to discontinuation.
Results: The study included 99 patients. At baseline, median epilepsy duration was 24 years and median number of seizures/months was 12.3. The median number of concomitant ASMs were 3. Mean CNB dosages/day were 117.1 mg, 165.9 mg, and 232.3 mg at 3, 6, and 12 months. Retention rates were 87.8%, 83.3%, and 87.0% at 3, 6, and 12 months. One third of patients (33/99) had “highly active” epilepsy (≥20 seizures per month) with an overall mean seizure frequency of 71.9 per month. The most frequent etiology was structural (n=65; 65.7%). At 3 months, 55 patients (64.7% of the total cohort) experienced more than a 50% seizure frequency reduction, 35 patients (35.4%) experienced a 75-99% seizure frequency reduction and 20 patients (23.5%) were seizure free. At 12 months, thirty-five patients (35.4% of the total cohort) experienced a 75%–90% seizure frequency reduction, and 35 patients (55.6% of the total cohort) had a 50%–74% seizure frequency reduction.
Conclusions: CNB demonstrated a strong response in this highly resistant group. Most AEs were mild to moderate, and very few resulted in stopping the medication.
Funding: none
Anti-seizure Medications